Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
US Army
Fish and Richardson
Healthtrust
Covington
Deloitte
Citi
Baxter
McKesson

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021453

« Back to Dashboard

NDA 021453 describes ZERIT XR, which is a drug marketed by Bristol Myers Squibb and is included in one NDA. There is one patent protecting this drug. Additional details are available on the ZERIT XR profile page.

The generic ingredient in ZERIT XR is stavudine. There are fourteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the stavudine profile page.
Summary for 021453
Tradename:ZERIT XR
Applicant:Bristol Myers Squibb
Ingredient:stavudine
Patents:1
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 021453

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE, EXTENDED RELEASE;ORALStrength37.5MG
Approval Date:Dec 31, 2002TE:RLD:No
Patent:➤ Sign UpPatent Expiration:Aug 18, 2023Product Flag?Substance Flag?Delist Request?Y

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE, EXTENDED RELEASE;ORALStrength50MG
Approval Date:Dec 31, 2002TE:RLD:No
Patent:➤ Sign UpPatent Expiration:Aug 18, 2023Product Flag?Substance Flag?Delist Request?Y

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE, EXTENDED RELEASE;ORALStrength75MG
Approval Date:Dec 31, 2002TE:RLD:No
Patent:➤ Sign UpPatent Expiration:Aug 18, 2023Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 021453

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers Squibb ZERIT XR stavudine CAPSULE, EXTENDED RELEASE;ORAL 021453-003 Dec 31, 2002 ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb ZERIT XR stavudine CAPSULE, EXTENDED RELEASE;ORAL 021453-004 Dec 31, 2002 ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb ZERIT XR stavudine CAPSULE, EXTENDED RELEASE;ORAL 021453-001 Dec 31, 2002 ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb ZERIT XR stavudine CAPSULE, EXTENDED RELEASE;ORAL 021453-002 Dec 31, 2002 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Chinese Patent Office
Harvard Business School
Boehringer Ingelheim
US Army
McKesson
Deloitte
Fuji
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.